Neoplasia/BPH

	A rule-based, feedback-driven framework for fully automated prostate VMAT planning. J Appl Clin Med Phys Sangster J, Taylor M, Jolly D, Gastaldo J, Lorenz F. PMID: 42638300 [PubMed - indexed for MEDLINE]
	Safety and Efficacy of Rezūm Water Vapor Energy Therapy for Benign Prostatic Hyperplasia With Continued Antithrombotic Therapy: A Comparative Study. Low Urin Tract Symptoms Fujisawa N, Washino S, Yasuda Y, Maiya S, Shinozaki T. PMID: 42638164 [PubMed - indexed for MEDLINE]
	Clinical impact of routine second‑opinion reading of [¹⁸F]FDG‑PET/CT in newly diagnosed invasive bladder cancer: A multicentre study in a centralised referral network. Eur J Nucl Med Mol Imaging Lijnen RAG, Vierling ML, Ringia JB, Hendricksen K, KleinJan GH, Postema AW, Vogel WV, Boellaard TN, Braat AJAT, Heijmen L, van Rhijn BWG, Mertens LS. PMID: 42637974 [PubMed - as supplied by publisher]
	Metallic versus polymeric ureteric stents for chronic malignant ureteric obstruction: a systematic review and meta-analysis. World J Urol Lim QY, Kyaw L, Ong CSH, Law YXT, Tiong HY. PMID: 42637852 [PubMed - indexed for MEDLINE]
	Comment on "Frailty burden and symptomatic BPH/LUTS in aging men: evidence from two nationally representative population-based studies". World J Urol Suman, Banu S, Kaur J. PMID: 42637883 [PubMed - in process]
	Post-translational modifications in prostate cancer: coordinated oncogenic networks and clinical implications. Biochim Biophys Acta Rev Cancer Ren H, Li X, Jiang Z, Bai Y, Ai J. PMID: 42637058 [PubMed - as supplied by publisher]
	High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial. Lancet Oncol Hennequin C, Sargos P, Roca L, Silva M, Latorzeff I, Peiffert D, Cozzi S, Benyoucef A, Hasbini A, Supiot S, Ronchin P, Wachter T, Azria D, Magne N, Zibouche M, Vial N, Cormier L. PMID: 42636837 [PubMed - indexed for MEDLINE]
	Nomograms for Predicting Recurrence and Oncologic Outcomes After Partial Nephrectomy for Renal Cell Carcinoma. Clin Genitourin Cancer Menezes Jesus VL, Dos Anjos GC, Alves GKJ, Sandoval EAA, Barros GG, Cho DH, Lima FVS, de Carvalho PA, Gallucci FP, Cardili L, Pontes J Junior, Nahas WC, Cordeiro MD. PMID: 42636730 [PubMed - as supplied by publisher]
	Interconnectedness of Factors Affecting Patient Willingness to Discuss Prostate Cancer Clinical Trials With Physicians. JCO Oncol Pract Liyanage JSS, Ong V, Hamel LM, Eggly S, Carducci MA, Lansey DG, Heath EI, Moore TF, Albrecht TL, Manning MA, Kim S. PMID: 42636423 [PubMed - as supplied by publisher]
	A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer. Cancer Res Commun Choudhury AD, Zhong C, Xie W, Kochupurakkal BS, Wu PI, Riaz IB, Liu R, Yang DD, Folefac E, Lee D, Parikh M, Einstein DJ, Kessler ER, Mayer T, McKay RR, Pace A, Mouw KW, Chen L, Adalsteinsson VA, Van Allen EM, Kunos CA, Gore SD, Das B, D'Andrea A, Taplin ME, Shapiro GI. PMID: 42636061 [PubMed - as supplied by publisher]
	A single-center study of prognostic impact and treatment implications of cribriform pattern in prostate cancer. Discov Oncol Handke A, Dellino M, Orf C, Wang N, Darr C, Bach P, Roghmann F, Tully KH. PMID: 42635876 [PubMed]
	Multimodal artificial intelligence in prostate cancer: integrating multiparametric MRI with clinicopathological, molecular, and functional imaging data. Abdom Radiol (NY) Fujiwara M, Yoshida S, Banerjee I, Arita Y, Fujii Y. PMID: 42635792 [PubMed - as supplied by publisher]
	Outcomes of [(177)Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study. Eur J Nucl Med Mol Imaging Arslan DF, Civan C, Sanli MO, Has Simsek D, Ekenel M, Basaran M, Erdem S, Ozcan F, Kuyumcu S, Sanli Y. PMID: 42635771 [PubMed - as supplied by publisher]
	Individual and composite socioeconomic inequalities in diagnosis, treatment, and survival of kidney cancer: a population-based analysis of the SEER database. World J Urol Zhang S, Sheng Y, Wang Y, Zhu S, Xiong H. PMID: 42635662 [PubMed - indexed for MEDLINE]
	Patient and primary care clinician perspectives on polygenic risk scores for prostate cancer screening: a national qualitative study. Genet Med Clayman ML, Cheam L, Gillespie C, Antwi AA, Anderson E, Danowski ME, Brunette CA, Song V, Grant CE, Scheuner MT, Wiener RS, Vassy JL. PMID: 42635031 [PubMed - as supplied by publisher]
	DYNAMIC ANDROGEN RESPONSE INDEX AND ITS ASSOCIATION WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT ANDROGEN DEPRIVATION THERAPY. Exp Oncol Afanasiev Y, Vozianov S, Danylets R, Grygorenko V, Shulyak O, Sosnin M, Kholokharenko I. PMID: 42634840 [PubMed - indexed for MEDLINE]
	The Synergistic Role of Phenolic Compounds in Docetaxel Chemoresistance in Prostate Cancer: A Systematic Review and Meta-Analysis. Curr Pharm Des Tatiparthi R, Aljabali AAA, Mishra Y, Mishra V. PMID: 42634543 [PubMed - as supplied by publisher]
	Editorial Comment on Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial. Int J Urol Utsumi T. PMID: 42634253 [PubMed - in process]
	Diet and risk of bladder cancer: a systematic review of epidemiological evidence. BJU Int Miyajima K, Miszczyk M, Roessler N, Inoue S, Rajwa P, Matsukawa A, Urabe F, Mori K, Yanagisawa T, Karakiewicz PI, Teoh JY, Briganti A, Yang L, Schernhammer E, Kimura T, Shariat SF. PMID: 42634248 [PubMed - as supplied by publisher]
	Skin Rash Management Based on Early Elevation in the Eosinophil Proportion Within 3 Months of Initiating Apalutamide for Prostate Cancer. Cancer Rep (Hoboken) Koguchi D, Tsumura H, Tabata KI, Satoh T, Tachibana T, Hirano S, Ikeda M, Ishii D, Matsumoto K. PMID: 42634213 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 190715

Page 1 of 9536



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy